Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers Positive Results

TLDR

Table of Contents

Ionis shares rise 2.58% after positive Phase 3 ulefnersen trial results emerge.
Ulefnersen meets the FUSION primary endpoint with strong statistical significance.
The FUS-ALS study also records improvements across several key secondary endpoints.
Otsuka plans FDA discussions and explores expedited regulatory approval pathways.
Ionis remains eligible for milestone payments and royalties under the Otsuka deal.

Ionis Pharmaceuticals shares rose 2.58% to $46.06 after the company announced positive Phase 3 results for ulefnersen. The experimental medicine met its primary endpoint in patients with a rare genetic form of amyotrophic lateral sclerosis. The outcome strengthens Ionis’ neurological pipeline and supports the next regulatory steps for the treatment.

Ionis Pharmaceuticals, Inc., IONS

Phase 3 FUSION Trial Meets Primary Endpoint

Ionis and Otsuka Pharmaceutical reported positive topline results from the Phase 3 FUSION study evaluating ulefnersen. The trial involved patients with ALS caused by mutations in the fused in sarcoma gene, known as FUS-ALS. Researchers developed ulefnersen to target the genetic cause of this rare and rapidly progressing form of ALS.

The study met its primary endpoint after showing statistically significant improvements against placebo across function and survival measures. Researchers assessed death, permanent ventilation, rescue treatment, and changes in the ALS Functional Rating Scale Revised. The primary analysis produced a p-value of 0.0005, supporting the statistical significance of the findings.

Ulefnersen also delivered statistically significant improvements across several important secondary endpoints included in the trial. These measures included serum neurofilament light chain levels and time to death, ventilation, rescue, or disease-related withdrawal. The companies also reported favorable safety and tolerability, while most adverse events remained mild or moderate.

Positive Results Advance Ulefnersen Toward Regulatory Review

The successful trial gives Ionis and Otsuka important clinical evidence as they prepare for discussions with global regulators. Otsuka plans to review the FUSION findings with the U.S. Food and Drug Administration. The company will also discuss possible expedited submission pathways with other health authorities.

Both companies plan to present detailed FUSION results at a future medical meeting. They also intend to submit the complete findings for publication in a peer-reviewed medical journal. Additional prespecified and exploratory analyses will further examine ulefnersen’s effects across the study population.

Ionis licensed ulefnersen to Otsuka in 2024 through a collaborative development and licensing agreement. Ionis received an upfront payment and remains eligible for additional regulatory and commercial milestone payments. The agreement also gives Ionis tiered royalties on future net sales if the treatment reaches the market.

FUSION Expands Ionis’ Genetic ALS Program

FUSION used a global, randomized, double-blind, placebo-controlled design to assess ulefnersen’s safety and effectiveness in FUS-ALS. Participants received either ulefnersen or placebo during a 72-week blinded treatment period. They later entered an open-label extension where all participants received ulefnersen.

The primary analysis included 73 participants and combined clinical function with several survival-related outcomes. Researchers also evaluated respiratory function, muscle strength, quality of life, and key biological markers. These additional measures will help define the treatment’s wider clinical profile during further analysis.

The program expands Ionis’ work in genetically targeted treatments for rare forms of ALS. Its earlier neurological development work also included QALSODY, which targets a different genetic cause of the disease. Ulefnersen now adds a successful Phase 3 program focused specifically on patients with FUS-related ALS.

✨ Limited Time Offer